



BioLight Life Sciences Ltd.

("The Company")

Subject: Completion of Human Subject Recruitment for a Study Examining Innovative Technology for Retinal Disease Diagnosis

May 20, 2025

The company is pleased to announce that on May 19, 2025, the processing of the last participant's sample in the clinical human feasibility study for the examination and evaluation of innovative technology for diagnosing retinal diseases using tears (the "**Clinical Feasibility Study**" and the "**Technology**") was completed.

A total of 40 human samples have been collected and processed to date. Of these, 30 samples are from patients at various stages of retinal disease, and 10 samples are from healthy subjects.

This announcement follows the company's immediate report dated December 11, 2024, regarding the receipt of interim results from 20 subjects, which supported the continuation of the Clinical Feasibility Study¹.

The company estimates that the final results of the Clinical Feasibility Study are expected to be received by the beginning of the third quarter of 2025.

Forward-Looking Information Disclaimer

The information, details, and assessments of the company contained in this section including the expected timing for receiving clinical feasibility study results, the potential of the clinical feasibility study and the technology, the results of the clinical feasibility study, its chances of success, and the potential for cooperation following it—constitute "forward-looking information" as defined in the Securities Law.

This information involves high uncertainty and is based, among other things, on third-party factors and numerous variables over which the company does not necessarily have

¹ See immediate report dated December 11, 2024 [Reference No.: 2024-01-623448], incorporated herein by reference.



control. Therefore, it is possible that the aforementioned information, details, and assessments may not materialize, may not materialize fully, or may materialize in a manner materially different from what was initially estimated or anticipated.

Sincerely,

BioLight Life Sciences Ltd.

NON-BINDING TRANSLATION

This immediate report is a free translation of the Company's immediate report in Hebrew published on the TASE on May 20, 2025. In the event of inconsistency between this version and the Hebrew one, the Hebrew language version shall prevail.